NR3C2 and Myocardial fibrosis: Non-depressor dose of eplerenone, a specific MR blocker, inhibited the large BP variability-induced MR activation, inflammatory changes, cardiac hypertrophy, and myocardial fibrosis and thereby prevented systolic dysfunction in SHR+SAD without changing BP variability (Fig. 6).